Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc.

World Rank (Aug-2026)
6450
Market Cap (Aug-2026)
1.939 Billion USD
Market Cap (Mar-08-2026)
1.252 Billion USD
World Rank (Jan-05-2024)
15,206
Market Cap (Jan-05-2024)
0.329 Billion USD
World Rank (Jul-30-2023)
25,824
Market Cap (Jul-30-2023)
0.044 Billion USD
World Rank (Jan-07-2022)
14,513
Market Cap (Jan-07-2022)
0.415 Billion USD
World Rank (Jan-01-2021)
7,943
Market Cap (Jan-01-2021)
1.002 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
TSHA
Employee Count
178
Employee Count as of Date
As on 2021
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
10 Million USD
Annual Operating Income in USD
-110 Million USD
Annual Net Income in USD
-109 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
343 Million USD
Total Liabilities in USD
96 Million USD
Total Equity in USD
247 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
TAYSHA GENE THERAPIES, INC.
Yahoo
Yahoo @ Nasdaq
Company Profile
Taysha Gene Therapies is a Biotechnology company focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) both in rare and large patient populations. It is having 10 employees as on 2019. The headquarters is in USA.
IPO Year
2020
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share